成纤维细胞生长因子23对血管平滑肌细胞表型和功能的直接作用
本研究通过体外、体内、离体实验及2-3期慢性肾脏病患者评估,探讨FGF23对血管平滑肌细胞表型的直接调控。体外实验显示高水平FGF23经FGFR1和Erk1/2下调miR-221/222,使血管平滑肌细胞由收缩型转为合成型;大鼠输注重组FGF23增加血管壁厚度并降低miR-221表达,主动脉环实验显示高FGF23增加动脉僵硬度。2-3期CKD患者中FGF23升高与脉搏波传导速度增加及血浆miR-221/222水平降低相关。
要点
- 高水平FGF23经FGFR1和Erk1/2下调miR-221/222,使血管平滑肌细胞由收缩型转为合成型。
- 转染miR-221/222可恢复血管平滑肌细胞的收缩表型。
- 2-3期CKD患者中FGF23升高与脉搏波传导速度增加及血浆miR-221/222降低相关。
核心结论
- 在血管平滑肌细胞中,高水平FGF23通过下调miR-221/222导致细胞向合成型表型转变,该改变增加动脉僵硬度并损害血管功能,可能最终加重心血管疾病。
研究设计与样本
- 研究包含体外、体内和离体实验,并评估2-3期慢性肾脏病患者中FGF23与血管功能障碍的关系。
主要发现
- 体外研究显示高水平FGF23作用于其特异性受体FGFR1和Erk1/2,使血管平滑肌细胞由收缩型转为合成型,该改变由miR-221/222下调介导,并上调MAP3K2和PAK1表达。
- 转染miR-221/222可恢复血管平滑肌细胞的收缩表型。
- 向大鼠输注重组FGF23增加血管壁厚度,血管平滑肌细胞呈合成型表型并伴miR-221表达降低。
- 离体主动脉环研究显示高FGF23增加动脉僵硬度。
- 2-3期CKD患者中FGF23升高与脉搏波传导速度增加及血浆miR-221/222水平降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In chronic kidney disease (CKD) patients, increased levels of fibroblast growth factor 23 (FGF23) are associated with cardiovascular mortality. The relationship between FGF23 and heart hypertrophy has been documented, however, it is not known whether FGF23 has an effect on vasculature. Vascular smooth muscle cells VSMCs may exhibit different phenotypes; our hypothesis is that FGF23 favours a switch from a contractile to synthetic phenotype that may cause vascular dysfunction. Our objective was to determine whether FGF23 may directly control a change in VSMC phenotype. METHODS: This study includes in vitro, in vivo and ex vivo experiments and evaluation of patients with CKD stages 2-3 studying a relationship between FGF23 and vascular dysfunction. RESULTS: In vitro studies show that high levels of FGF23, by acting on its specific receptor FGFR1 and Erk1/2, causes a change in the phenotype of VSMCs from contractile to synthetic. This change is mediated by a downregulation of miR-221/222, which augments the expression of MAP3K2 and PAK1. miR-221/222 transfections recovered the contractile phenotype of VSMCs. Infusion of recombinant FGF23 to rats increased vascular wall thickness, with VSMCs showing a synthetic phenotype with a reduction of miR-221 expression. Ex-vivo studies on aortic rings demonstrate also that high FGF23 increases arterial stiffening. In CKD 2-3 patients, elevation of FGF23 was associated with increased pulse wave velocity and reduced plasma levels of miR-221/222. CONCLUSION: In VSMCs, high levels of FGF23, through the downregulation of miR-221/222, causes a change to a synthetic phenotype. This change in VSMCs increases arterial stiffening and impairs vascular function, which might ultimately worsen cardiovascular disease.
引用
- Vergara N, de Mier MVP, Rodelo-Haad C, et al. The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function. Nephrol Dial Transplant. 2023. PMID: 35867864. doi:10.1093/ndt/gfac220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。